Online inquiry

IVTScrip™ mRNA-Human Alkaline phosphatase, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK16022MR)

This product GTTS-WK16022MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the Alkaline phosphatase protein. This product can be used in Pluripotent stem cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_031313.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 251
UniProt ID P10696
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human Alkaline phosphatase, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK16022MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK4444MR IVTScrip™ mRNA-Human AID, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AID
GTTS-WK19013MR IVTScrip™ mRNA-Human ALG13, (Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ALG13
GTTS-WK12483MR IVTScrip™ mRNA-Human ACYP2, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACYP2
GTTS-WK7639MR IVTScrip™ mRNA-Human ACP2, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACP2
GTTS-WK21875MR IVTScrip™ mRNA-Human ATP11A, (Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ATP11A
GTTS-WK15107MR IVTScrip™ mRNA-Human ALDHA1, (Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALDHA1
GTTS-WK27129MR IVTScrip™ mRNA-Human ARIH1, (Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ARIH1
GTTS-WK9429MR IVTScrip™ mRNA-Human ACLY, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACLY
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW